GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.02 USD | -10.36% |
|
+64.58% | -34.38% |
| May. 21 | Top Midday Decliners | MT |
| May. 21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 | 6.931 |
| Enterprise Value (EV) 1 | 5.462 | 35.83 | 93.05 | 28.84 | 10.56 | 6.931 |
| P/E ratio | -0.12 x | -1.12 x | -1.48 x | -1.34 x | -1.36 x | -0.46 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | -5,960,929 x | - | - | - |
| FCF Yield | - | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 132 | 166 | 1,017 | 1,085 | 1,381 | 1,381 |
| Reference price 2 | 41.31 | 216.2 | 91.50 | 26.57 | 7.650 | 5.020 |
| Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -6.764 | -57.52 | -21.26 | -13.58 | -17.41 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -28.3 | -58.01 | -20.88 | -7.597 | -17.41 |
| Net income 1 | -38.65 | -28.3 | -58.01 | -20.88 | -7.597 | -17.41 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -341.7 | -193.5 | -61.80 | -19.80 | -5.640 | -10.80 |
| Free Cash Flow | - | - | -15.61 | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.18 | -5.442 | -3.014 | -7.023 | -5.778 | -3.665 | -3.621 | -3.122 | -3.168 | -3.091 | -4.208 | -4.519 | -4.805 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 | -4.208 | -4.519 | -4.805 |
| Net income 1 | -18.02 | -5.44 | -2.979 | -6.881 | -5.584 | -0.227 | -1.992 | -2.416 | -2.962 | -2.266 | -4.208 | -4.519 | -4.805 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -15.60 | -5.100 | -3.000 | -6.600 | -5.400 | -0.3000 | -1.500 | -1.800 | -5.520 | -1.640 | -2.700 | -2.700 | -3.000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 10/31/22 | 3/30/23 | 5/15/23 | 8/7/23 | 11/1/23 | 3/26/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | -15.6 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/27/20 | 4/16/21 | 3/28/22 | 3/30/23 | 3/26/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.02
USD
Average target price
150
USD
Spread / Average Target
+2,888.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.38% | 6.93M | |
| +37.74% | 723B | |
| +32.22% | 595B | |
| -2.07% | 369B | |
| +20.25% | 332B | |
| +2.99% | 282B | |
| +16.60% | 244B | |
| +9.77% | 208B | |
| -5.15% | 205B | |
| +7.43% | 166B |
- Stock Market
- Equities
- GTBP Stock
- Financials GT Biopharma, Inc.
